CMPS - COMPASS Pathways plc

NasdaqGS - NasdaqGS Real-time price. Currency in USD
8.06
-0.20 (-2.42%)
At close: 04:00PM EDT
8.20 +0.14 (+1.74%)
Pre-market: 08:30AM EDT
Stock chart is not supported by your current browser
Previous close8.26
Open8.30
Bid0.00 x 800
Ask0.00 x 800
Day's range7.90 - 8.30
52-week range6.97 - 21.50
Volume164,066
Avg. volume265,126
Market cap367.711M
Beta (5Y monthly)2.50
PE ratio (TTM)N/A
EPS (TTM)-2.45
Earnings date11 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est42.30
  • Globe Newswire

    COMPASS Pathways' key patents upheld by the US Patent and Trademark Office

    PTAB rejects two requests for rehearing of the USPTO's decision denying institution of post-grant review (PGR) of U.S. patent numbers 10,947,257 (‘257 Patent) and 10,954,259 (‘259 Patent).In June 2022, the PTAB denied institution of the PGRs finding the challenger failed to establish that any of the claims of ‘257 Patent and ‘259 Patent are unpatentable. LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient a

  • Globe Newswire

    COMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation Officer

    She will remain a member of the COMPASS Pathways Board of DirectorsLONDON, May 31, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation, today announced that Co-founder and Chief Innovation Officer Dr. Ekaterina Malievskaia will step down from her executive role effective June 16, 2023. She will remain a member of the COMPASS Pathways Board of Directors, while her executive res

  • Globe Newswire

    COMPASS Pathways to participate in upcoming Jefferies Healthcare Conference

    LONDON, May 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Jefferies Healthcare Conference at 3:30 pm ET on June 8, 2023. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be accessible for 30 days f

  • Globe Newswire

    Data Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023

    More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study, conducted by Sunstone Therapies and scheduled to be presented at the ASCO annual meeting on June 5, is believed to be the longest clinical study of psilocybin ever conducted LONDON, May 26, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated

  • Motley Fool

    Compass Pathways Plc (CMPS) Q1 2023 Earnings Call Transcript

    Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS)Q1 2023 Earnings CallMay 11, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day and thank you for standing by.

  • Globe Newswire

    COMPASS Pathways Announces First Quarter 2023 Financial Results and Business Highlights

    LONDON, May 11, 2023 (GLOBE NEWSWIRE) -- Highlights: COMP360 Phase 3 pivotal program underway, patients have been treated in both trialsCPT® III code for in-person psychedelic therapy support accepted by the American Medical AssociationCash position at 31 March 2023 of $117.1 million, additional $26.9 million net cash raised through ATM facility to date in the second quarterConference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care compan

  • Motley Fool

    This Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's Why

    After a sharp rally in 2021, most stocks in the biotech industry's psychedelic segment are a shadow of their former selves. It'll be some time before the details surrounding the codes are finalized and won't be published in full until July of this year.

  • Globe Newswire

    COMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023

    LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2023, and provide an update on recent business developments on 11 May 2023. The management team will host a conference call at 8:00am ET (1:00pm UK) on 11 May 2023. To access the call, please register in advance here to obtain a

  • Globe Newswire

    American Medical Association to Issue First New Code for Psychedelic Therapies

    COMPASS Pathways and MAPS PBC submitted joint application for new code to facilitate access to psychedelic therapy in the US, if approvedLONDON and SAN JOSE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (COMPASS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and MAPS Public Benefit Corporation (MAPS PBC), a clinical-stage company dedicated to changing the way mental health conditions are treat

  • Motley Fool

    After Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?

    With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences (NASDAQ: ATAI) is having a rough go of things lately. When faced with such a discrepancy between recent performance and projected future returns, investors are right to hesitate to invest in this super-risky biotech stock. Let's take a peek at what's going wrong with Atai so that we can figure out if it's capable of surviving in the near term, and if it is, whether that makes it a buy.

  • Globe Newswire

    COMPASS Pathways to participate in upcoming 22nd Annual Needham Virtual Healthcare Conference

    LONDON, April 10, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 22nd Annual Needham Virtual Healthcare Conference at 9:30 am ET on April 19, 2023. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be ac

  • Motley Fool

    2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market

    Enterprising investors who pay attention to this can set themselves up for future success by buying into great growth stocks while in the hard landing phase of the volatility. Two biopharma stocks are particularly appealing right now as buy candidates before the next bull market has a chance to buoy their shares once again. It develops liquid biopsies for cancer screening, treatment selection, treatment efficacy evaluation, and recurrence detection, which means that patients don't need to experience the invasiveness of a traditional biopsy to get the health information their doctors need to determine a course of treatment.

  • Motley Fool

    2 Growth Stocks With Incredible Potential in the Next 5 Years

    Specifically, there are no guarantees that positive early results will lead to positive later-stage clinical trials results, despite yearslong efforts put in to develop these drugs and therapies. More often than not, pharma and biotech investors can only gauge the chances of a company's success by weighing the results of its clinical trials against its available cash runway.

  • Globe Newswire

    COMPASS Pathways to participate in upcoming Cowen 43rd Annual Health Care Conference, Oppenheimer 33rd Annual Healthcare Conference, and Loop Capital Investor Conference

    LONDON, March 02, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in three upcoming events as follows: Cowen 43rd Annual Health Care Conference: ‘Neuropsych Panel’ at 12:50pm ET on March 6, 2023 and host investor meetingsOppenheimer 33rd Annual Healthcare Conference: presentation at 10:00am ET on March 13, 2023 and hos

  • Motley Fool

    Compass Pathways Plc (CMPS) Q4 2022 Earnings Call Transcript

    Again, my name is Steve Schultz. Dr. Guy Goodwin, our chief medical officer, is unable to join us today, so Kabir will be covering clinical development. Before we begin, let me remind everyone that during the call today, the team will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended.

  • Globe Newswire

    COMPASS Pathways Announces Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

    Highlights: Phase 3 pivotal program underway - important updates announcedPhase 3 long term follow up definedCash position at 31 December 2022 of $143.2 millionConference call today at 8:00am ET (1:00pm UK) LONDON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter and year-end 2022 and gav

  • Globe Newswire

    COMPASS Pathways plc to announce fourth quarter and year-end 2022 financial results on 28 February 2023

    Conference call to be held at 8:00am ET (1:00pm UK)LONDON, Feb. 24, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2022, and provide an update on recent business developments on 28 February 2023. The management team will host a conference call at 8:00am ET (1:00pm UK) on 28 Fe

  • Motley Fool

    3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street

    Analysts are bearish, for example, on the three stocks that have helped the most in Wood's Ark Innovation ETF (NYSEMKT: ARKK) trouncing the market so far in 2023. Here are three Cathie Wood stocks that could more than double in 12 months, according to Wall Street. Wood owns shares of Intellia Therapeutics (NASDAQ: NTLA) in two of her ETFs -- the flagship Ark Innovation ETF and the Ark Genomic Revolution ETF (NYSEMKT: ARKG).

  • Zacks

    Is Cardinal Health (CAH) Stock Outpacing Its Medical Peers This Year?

    Here is how Cardinal Health (CAH) and COMPASS Pathways PLC Sponsored ADR (CMPS) have performed compared to their sector so far this year.

  • Zacks

    All You Need to Know About COMPASS Pathways PLC Sponsored ADR (CMPS) Rating Upgrade to Strong Buy

    COMPASS Pathways PLC Sponsored ADR (CMPS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

  • Zacks

    Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?

    Here is how COMPASS Pathways PLC Sponsored ADR (CMPS) and Geron (GERN) have performed compared to their sector so far this year.

  • Globe Newswire

    COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

    12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder New data from COMPASS’ phase 2b trial, also presented at ACNP, validate potential of COMP360 psilocybin therapy in treatment-resistant depression LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to acc

  • Motley Fool

    3 Big Trends Shaking Up Psychedelic Stocks

    Just as the idea of using psychedelic medicines to treat mental illnesses is gaining traction in society, psychedelics-focused biotech companies are becoming legitimate and lucrative investments that could help your portfolio in the future. Before you can appreciate which psychedelics players are worth investing in, you'll need to get a feeling for where the industry is going and how it's changing. As inflation surges in the U.S., the Federal Reserve is trying to stop it by hiking the federal funds rate, which ultimately determines how much interest companies need to pay when they take out fresh debt.

  • Globe Newswire

    COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

    LONDON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx Conference at 9:15am ET on 30 November 2022. A live audio webcast of the fireside chat will be accessible from the “Events” page of the Investors section of the COMPASS website. The replay of the webcast will be acc

  • Motley Fool

    COMPASS Pathways plc (CMPS) Q3 2022 Earnings Call Transcript

    Image source: The Motley Fool. COMPASS Pathways plc (NASDAQ: CMPS)Q3 2022 Earnings CallNov 03, 2022, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, ladies and gentlemen.